Subdued Growth No Barrier To Innate Pharma S.A. (EPA:IPH) With Shares Advancing 37%
Dec 20
Have your own idea? Try our Stock Screener
French (CAC) Healthcare Sector Analysis
UpdatedDec 21, 2024
DataAggregated Company Financials
Companies64
- 7D0.5%
- 3M-1.9%
- 1Y4.6%
- YTD3.3%
In the last week, the Healthcare industry is flat overall, with Sartorius Stedim Biotech standing out by going down 4.6%. As for the the longer term, the industry is up 4.6% over the past 12 months. As for the next few years, earnings are expected to grow by 17% per annum.
Sector Valuation and Performance
Has the French Healthcare Sector valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 22 Dec 2024 | €279.4b | €113.9b | €9.1b | 21.7x | 30.9x | 2.5x |
| Tue, 19 Nov 2024 | €276.5b | €113.9b | €9.1b | 21.3x | 30.5x | 2.4x |
| Thu, 17 Oct 2024 | €286.6b | €112.6b | €8.8b | 23.1x | 32.5x | 2.5x |
| Sat, 14 Sep 2024 | €288.1b | €112.0b | €8.6b | 22x | 33.7x | 2.6x |
| Mon, 12 Aug 2024 | €276.8b | €111.8b | €8.6b | 22.9x | 32.3x | 2.5x |
| Wed, 10 Jul 2024 | €262.6b | €110.0b | €9.0b | 22.9x | 29x | 2.4x |
| Fri, 07 Jun 2024 | €274.3b | €110.0b | €9.0b | 25.1x | 30.4x | 2.5x |
| Sun, 05 May 2024 | €269.9b | €104.9b | €7.6b | 23.9x | 35.6x | 2.6x |
| Tue, 02 Apr 2024 | €278.7b | €104.7b | €8.6b | 21x | 32.4x | 2.7x |
| Thu, 29 Feb 2024 | €268.3b | €104.2b | €8.9b | 20.7x | 30x | 2.6x |
| Sat, 27 Jan 2024 | €264.7b | €104.0b | €12.7b | 21.2x | 20.9x | 2.5x |
| Mon, 25 Dec 2023 | €261.9b | €104.0b | €12.7b | 21.2x | 20.6x | 2.5x |
| Wed, 22 Nov 2023 | €248.0b | €104.0b | €12.7b | 20.4x | 19.5x | 2.4x |
| Fri, 20 Oct 2023 | €256.7b | €104.8b | €12.5b | 18.7x | 20.6x | 2.5x |
| Sun, 17 Sep 2023 | €279.2b | €104.8b | €12.4b | 21.4x | 22.6x | 2.7x |
| Tue, 15 Aug 2023 | €274.4b | €104.5b | €12.5b | 21.3x | 22x | 2.6x |
| Thu, 13 Jul 2023 | €262.4b | €103.8b | €12.4b | 19.6x | 21.1x | 2.5x |
| Sat, 10 Jun 2023 | €265.1b | €108.3b | €12.1b | 20x | 21.9x | 2.4x |
| Mon, 08 May 2023 | €280.9b | €108.3b | €12.1b | 21.6x | 23.3x | 2.6x |
| Wed, 05 Apr 2023 | €268.3b | €107.8b | €12.4b | 19.9x | 21.6x | 2.5x |
| Fri, 03 Mar 2023 | €259.7b | €107.7b | €12.8b | 19.5x | 20.3x | 2.4x |
| Sun, 29 Jan 2023 | €263.7b | €104.9b | €10.5b | 18.2x | 25.1x | 2.5x |
| Tue, 27 Dec 2022 | €264.8b | €104.9b | €10.5b | 17.8x | 25.2x | 2.5x |
| Thu, 24 Nov 2022 | €266.0b | €105.0b | €10.2b | 18.2x | 26x | 2.5x |
| Sat, 22 Oct 2022 | €245.6b | €102.5b | €10.4b | 17.4x | 23.7x | 2.4x |
| Mon, 19 Sep 2022 | €182.7b | €79.2b | €9.0b | 17.7x | 20.2x | 2.3x |
| Wed, 17 Aug 2022 | €200.1b | €78.8b | €9.0b | 21.7x | 22.1x | 2.5x |
| Fri, 15 Jul 2022 | €208.3b | €76.6b | €9.1b | 19.9x | 23x | 2.7x |
| Sun, 12 Jun 2022 | €204.2b | €76.4b | €9.2b | 18.7x | 22.2x | 2.7x |
| Tue, 10 May 2022 | €202.3b | €75.6b | €9.3b | 18.1x | 21.9x | 2.7x |
| Thu, 07 Apr 2022 | €220.3b | €74.3b | €8.7b | 21.3x | 25.3x | 3x |
| Sat, 05 Mar 2022 | €194.0b | €73.8b | €8.5b | 17.9x | 22.9x | 2.6x |
| Mon, 31 Jan 2022 | €211.4b | €71.8b | €8.5b | 19.2x | 24.8x | 2.9x |
| Wed, 29 Dec 2021 | €227.0b | €71.8b | €8.5b | 24.7x | 26.6x | 3.2x |
Price to Earnings Ratio
26.6x
Current Industry PE
- Investors are optimistic on the French Healthcare industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 30.9x which is higher than its 3-year average PE of 25.3x.
- The industry is trading close to its 3-year average PS ratio of 2.6x.
Past Earnings Growth
- The earnings for companies in the Healthcare industry have grown 2.0% per year over the last three years.
- Revenues for these companies have grown 17% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the French Healthcare sector?
| FR Market | -1.72% | |
| Healthcare | 0.51% | |
| Pharma | 1.96% | |
| Healthtech | 1.21% | |
| Medical Equipment | 0.0035% | |
| Biotech | -2.53% | |
| Life Sciences | -3.09% | |
| Healthcare Services | -3.70% | |
Industry PE
- Investors are most optimistic about the Life Sciences industry which is trading above its 3-year average PE ratio of 40.1x.
- Analysts are expecting annual earnings growth of 27.4%, which is higher than its past year's earnings decline of 33.7% per year.
Forecasted Growth
- Analysts are most optimistic on the Life Sciences industry, expecting annual earnings growth of 27% over the next 5 years.
- This is better than its past earnings decline of 34% per year.
- In contrast, the Healthcare Services industry is expected to see its earnings grow by 3.0% per year over the next few years.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| SAN Sanofi | €91.28 | 2.4% +€2.6b | 2.2% | PE25.4x | |
| EQS Equasens Société anonyme | €43.25 | 3.0% +€18.8m | -29.6% | PE15.4x | |
| VLA Valneva | €1.92 | 5.1% +€15.1m | -57.7% | PS2x | |
| MEDCL MedinCell | €16.80 | 3.1% +€14.6m | 153.0% | PS37.2x | |
| BIM bioMérieux | €102.20 | 0.1% +€11.8m | 1.2% | PE29.3x |
